Janux Therapeutics (JANX) Operating Expenses (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Operating Expenses data on file, last reported at $37.9 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $37.9 million, up 8.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $170.7 million (up 38.88% YoY), and the FY2025 annual result was $167.7 million, up 53.21% from the prior year.
• Operating Expenses retreated to $37.9 million in Q1 2026 per JANX's latest filing, from $42.4 million in the prior quarter.
• Over five years, Operating Expenses peaked at $45.3 million in Q3 2025 and troughed at $15.1 million in Q1 2022.
• A 5-year average of $27.8 million and a median of $22.3 million in 2023 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses soared 467.98% in 2022, then fell 11.9% in 2023.
• A 5-year view of Operating Expenses shows it stood at $21.1 million in 2022, then declined by 11.9% to $18.6 million in 2023, then soared by 56.05% to $29.0 million in 2024, then surged by 46.1% to $42.4 million in 2025, then dropped by 10.51% to $37.9 million in 2026.
• Business Quant data shows JANX's Operating Expenses at $37.9 million in Q1 2026, $42.4 million in Q4 2025, and $45.3 million in Q3 2025.